Skip to main navigation Skip to search Skip to main content

The ACS National Surgical Quality Improvement Program - Inflammatory Bowel Disease Collaborative: Design, Implementation, and Validation of a Disease-specific Module

  • Samuel Eisenstein
  • , Stefan D. Holubar
  • , Nicholas Hilbert
  • , Liliana Bordeianou
  • , Lynne A. Crawford
  • , Bruce Hall
  • , Tracy Hull
  • , Neil Hyman
  • , Megan Keenan
  • , Hiroko Kunitake
  • , Edward C. Lee
  • , William D. Lewis
  • , David Maron
  • , Evangelos Messaris
  • , Reba Miller
  • , Matthew Mutch
  • , Gail Ortenzi
  • , Sonia Ramamoorthy
  • , Radhika Smith
  • , Randolph M. Steinhagen
  • Steven D. Wexner

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Surgery for inflammatory bowel disease (IBD) involves a complex interplay between disease, surgery, and medications, exposing patients to increased risk of postoperative complications. Surgical best practices have been largely based on single-institution results and meta-analyses, with multicenter clinical data lacking. The American College of Surgeons National Surgical Quality Improvement Project (ACS-NSQIP) has revolutionized the way in which large-volume surgical outcomes data have been collected. Our aim was to employ the ACS-NSQIP to collect disease-specific variables relevant to surgical outcomes in IBD. Study Design: A collaborative of 13 high-volume IBD surgery centers was convened to collect 5 IBD-specific variables in NSQIP. Variables included biologic and immunomodulator medications usage, ileostomy utilization, ileal pouch anastomotic technique, and colonic dysplasia/neoplasia. A sample of the Surgical Clinical Reviewer collected data was validated by a colorectal surgeon at each institution, and kappa's agreement statistics generated. Results: Over 1 year, data were collected on a total of 956 cases. Overall, 41.4% of patients had taken a biologic agent in the 60 days before surgery. The 2 most commonly performed procedures were laparoscopic ileocolic resections (159 cases) and subtotal colectomies (151 cases). Overall, 56.8% of cases employed an ileostomy, and 134 ileal pouches were constructed, of which 92.4% used stapled technique. A sample of 214 (22.4%) consecutive cases was validated from 8 institutions. All 5 novel variables were shown to be reliably collected, with excellent agreement for 4 variables (kappa ≥ 0.70) and very good agreement for the presence of colonic dysplasia (kappa = 0.68). Conclusion: We report the results of the initial year of implementation of the first disease-specific collaborative within NSQIP. The selected variables were demonstrated to be reliably collected, and this collaborative will facilitate high-quality, large case-volume research specific to the IBD patient population.

Original languageEnglish
Pages (from-to)1731-1739
Number of pages9
JournalInflammatory Bowel Diseases
Volume25
Issue number11
DOIs
StatePublished - 18 Oct 2019

Keywords

  • ACS-NSQIP
  • Crohn's disease
  • biologic
  • colectomy
  • colorectal cancer
  • dysplasia
  • ileal pouch anal anastomosis
  • immunomodulator
  • inflammatory bowel disease
  • laparoscopy
  • ulcerative colitis

Fingerprint

Dive into the research topics of 'The ACS National Surgical Quality Improvement Program - Inflammatory Bowel Disease Collaborative: Design, Implementation, and Validation of a Disease-specific Module'. Together they form a unique fingerprint.

Cite this